TY - JOUR
T1 - The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury
T2 - Insights from the American Registry for Migraine Research
AU - Leibovit-Reiben, Zachary
AU - Ishii, Ryotaro
AU - Dodick, David W.
AU - Dumkrieger, Gina
AU - Cortez, Melissa M.
AU - Brennan, Kevin C.
AU - Digre, Kathleen
AU - Schwedt, Todd J.
N1 - Funding Information:
The authors gratefully acknowledge the American Registry for Migraine Research (ARMR) for the use of registry data to conduct this research. In addition, we would like to thank the patients and clinicians who participated in this registry.
Funding Information:
Zachary Leibovit‐Reiben has nothing to disclose. Todd Schwedt, within the last 12 months, has served as a consultant for Abbvie, Allergan, Biohaven, Click Therapeutics, Eli Lilly, Equinox, Ipsen, Lundbeck, Novartis, and Tonix. He has stock options in Aural Analytics and Nocira. He has received royalties from UpToDate. He has received research funding from: Amgen, American Migraine Foundation, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, and U.S. Department of Defense. He serves on the Board of Directors for the American Headache Society and the International Headache Society. Ryotaro Ishii, within the last 12 months, has served as a consultant for Amgen K.K., Eli Lilly Japan K.K., DAIICHI SANKYO COMPANY, LIMITED, and Otsuka Pharmaceutical Co., Ltd. He has received lecture fees from Amgen K.K., Eli Lilly Japan K.K., DAIICHI SANKYO COMPANY, LIMITED, Otsuka Pharmaceutical Co., Ltd, and Takeda Pharmaceutical Co., Ltd. Gina Dumkrieger has nothing to disclose. David W. Dodick reports the following conflicts within the past 12 months: consulting for AEON, Amgen, Atria, Clexio, Cerecin, Cooltech, Ctrl M, Allergan, Alder, Biohaven, GSK, Linpharma, Lundbeck, Promius, Eli Lilly, eNeura, Novartis, Impel, Satsuma, Theranica, WL Gore, Nocira, XoC, Zosano, Upjohn (Division of Pfizer), Pieris, Praxis, Revance, Equinox; honoraria from Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, Southern Headache Society (MAHEC), WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press; research support from Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI); stock options/shareholder/patents/board of directors for Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (Options), Theranica (Options), Second Opinion/Mobile Health (Options), Epien (Options/Board), Nocira (options), Matterhorn (Shares/Board), Ontologics (Shares/Board), King‐Devick Technologies (Options/Board), Precon Health (Options/Board); patent 17189376.1‐1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis. Melissa Cortez served as a consultant for Eli Lilly, and has received research funding from Amgen Early Investigator Award in Migraine Research and National Institutes of Health (1K23NS105920, 1R21HD100897). KC Brennan served as a consultant for Allergan/Abbvie in the past 12 months. He has research support from the NIH and the Department of Defense. Kathleen Digre has nothing to disclose; she is supported in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah.
Publisher Copyright:
© 2022 American Headache Society.
PY - 2022/5
Y1 - 2022/5
N2 - Objective: To investigate the impact of having headaches prior to traumatic brain injury (TBI) on headache features and long-term patient health outcomes. Background and Methods: This was an exploratory analysis of patients with TBI who were enrolled in the American Registry for Migraine Research (ARMR), a multicenter, prospective, longitudinal patient registry composed of patients with International Classification of Headache Disorders, 3rd edition (ICHD-3)–defined headache diagnoses. The ARMR study enrolled 2,707 patients between February 1, 2016 and May 6, 2020, 565 of whom qualified for this analysis. Those with headaches prior to their TBI were compared to those without headaches prior to their TBI for ICHD-3 diagnoses, headache frequency and intensity, headache-related disability (Migraine Disability Assessment score), symptoms of anxiety (General Anxiety Disorder [GAD-7]), depression (two items from Patient Health Questionnaire-9), post-traumatic stress disorder (PTSD), cutaneous allodynia (12-item Allodynia Symptom Checklist [ASC-12]), cognitive dysfunction (Migraine Attacks Subjective Cognitive Impairments Scale [Mig-SCog]), pain interference (Patient-Reported Outcomes Measurement Information System-Pain Interference), and work productivity (Work Productivity and Activity Impairment). Results: Among 565 participants with TBI, 350 had headaches prior to their TBI. Those with pre-TBI headaches were less likely to receive a diagnosis of post-traumatic headache (PTH; 14/350 [4.0%] vs. 21/215 [9.8%], p = 0.006), even though 25.7% reported new or worsening headaches within 7 days of their TBI. Those with pre-TBI headaches had higher ASC-12 scores (2.4 ± 3.5 vs. 1.8 ± 3.4, p = 0.030), Mig-SCog scores (9.3 ± 4.7 vs. 8 ± 4.9, p = 0.004), and GAD-7 scores (6.9 ± 5.1 vs. 6.2 ± 5.4, p = 0.039), and were more likely to have a migraine diagnosis (335/350 [95.7%] vs. 192/215 [89.3%], p = 0.003). Conclusions: Those with headaches prior to TBI are less likely to receive a diagnosis of PTH. They have more severe symptoms of cutaneous allodynia, cognitive impairment, and generalized anxiety. This analysis suggests that pre-TBI headaches might impact post-TBI headache diagnoses and associated features.
AB - Objective: To investigate the impact of having headaches prior to traumatic brain injury (TBI) on headache features and long-term patient health outcomes. Background and Methods: This was an exploratory analysis of patients with TBI who were enrolled in the American Registry for Migraine Research (ARMR), a multicenter, prospective, longitudinal patient registry composed of patients with International Classification of Headache Disorders, 3rd edition (ICHD-3)–defined headache diagnoses. The ARMR study enrolled 2,707 patients between February 1, 2016 and May 6, 2020, 565 of whom qualified for this analysis. Those with headaches prior to their TBI were compared to those without headaches prior to their TBI for ICHD-3 diagnoses, headache frequency and intensity, headache-related disability (Migraine Disability Assessment score), symptoms of anxiety (General Anxiety Disorder [GAD-7]), depression (two items from Patient Health Questionnaire-9), post-traumatic stress disorder (PTSD), cutaneous allodynia (12-item Allodynia Symptom Checklist [ASC-12]), cognitive dysfunction (Migraine Attacks Subjective Cognitive Impairments Scale [Mig-SCog]), pain interference (Patient-Reported Outcomes Measurement Information System-Pain Interference), and work productivity (Work Productivity and Activity Impairment). Results: Among 565 participants with TBI, 350 had headaches prior to their TBI. Those with pre-TBI headaches were less likely to receive a diagnosis of post-traumatic headache (PTH; 14/350 [4.0%] vs. 21/215 [9.8%], p = 0.006), even though 25.7% reported new or worsening headaches within 7 days of their TBI. Those with pre-TBI headaches had higher ASC-12 scores (2.4 ± 3.5 vs. 1.8 ± 3.4, p = 0.030), Mig-SCog scores (9.3 ± 4.7 vs. 8 ± 4.9, p = 0.004), and GAD-7 scores (6.9 ± 5.1 vs. 6.2 ± 5.4, p = 0.039), and were more likely to have a migraine diagnosis (335/350 [95.7%] vs. 192/215 [89.3%], p = 0.003). Conclusions: Those with headaches prior to TBI are less likely to receive a diagnosis of PTH. They have more severe symptoms of cutaneous allodynia, cognitive impairment, and generalized anxiety. This analysis suggests that pre-TBI headaches might impact post-TBI headache diagnoses and associated features.
KW - concussion
KW - headache
KW - migraine
KW - post-concussion syndrome
KW - post-traumatic headache (PTH)
KW - traumatic brain injury (TBI)
UR - http://www.scopus.com/inward/record.url?scp=85130375478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130375478&partnerID=8YFLogxK
U2 - 10.1111/head.14311
DO - 10.1111/head.14311
M3 - Article
C2 - 35593782
AN - SCOPUS:85130375478
SN - 0017-8748
VL - 62
SP - 566
EP - 576
JO - Headache
JF - Headache
IS - 5
ER -